Curcumin Enhances Ibrutinib Induced Killing Effect Against TP53-Mutated Chronic Lymphocytic Leukemia Cells in Vitro

被引：1

作者：

Zhang, Yunxia ^{[1
]}

Lei, Haohao ^{[1
]}

Wei, Xiaolei ^{[1
]}

Wei, Yongqiang ^{[1
]}

Feng, Ru ^{[1
]}

Guo, Xutao ^{[1
]}

机构：

[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-179874

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Curcumin enhances ibrutinib induced killing effect against TP53-mutated chronic lymphocytic leukemia cells in vitro
Zhang, Yunxia
Guo, Xutao
Feng, Ru
Wei, Xiaolei
Wei, Yongqiang
Lei, Haohao
LEUKEMIA & LYMPHOMA, 2023, 64 : S118 - S119
[2] Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib
Guarini, Anna
Peragine, Nadia
Messina, Monica
Marinelli, Marilisa
Ilari, Caterina
Cafforio, Luciana
Raponi, Sara
Bonina, Silvia
Mariglia, Paola
Mauro, Francesca R.
Gaidano, Gianluca
Del Giudice, Ilaria
Foa, Robin
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (03) : 392 - 396
[3] Treatment patterns and outcomes of patients with TP53-mutated chronic lymphocytic leukemia
Hwang, Steven
Wang, Yucai
Rabe, Kari
Williams-Watley, Marquise
Kenderian, Saad
Muchtar, Eli
Hampel, Paul
Kay, Neil
Koehler, Amber
Behnken, Amy
Leis, Jose
Braggio, Esteban
Shi, Min
Viswanatha, David
Van Dyke, Daniel
Slager, Susan
Parikh, Sameer
He, Rong
Ding, Wei
LEUKEMIA & LYMPHOMA, 2023, 64 : S84 - S85
[4] PRIMA-1MET cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells
Jaskova, Zuzana
Pavlova, Sarka
Malcikova, Jitka
Brychtova, Yvona
Trbusek, Martin
LEUKEMIA RESEARCH, 2020, 89
[5] Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations
Ahn, Inhye E.
Tian, Xin
Wiestner, Adrian
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (05): : 498 - 500
[6] Prognostic Impact of NOTCH1 Hotspot Mutation in TP53-Mutated Patients with Chronic Lymphocytic Leukemia
Kantorova, Barbara
Malcikova, Jitka
Navrkalova, Veronika
Smardova, Jana
Brazdilova, Kamila
Plevova, Karla
Diviskova, Eva
Borsky, Marek
Pavlova, Sarka
Tom, Nikola
Pal, Karol
Trbusek, Martin
Oltova, Alexandra
Brychtova, Yvona
Doubek, Michael
Mayer, Jiri
Pospisilova, Sarka
BLOOD, 2014, 124 (21)
[7] IBRUTINIB IS ACTIVE IN TP53-ABERRANT CHRONIC LYMPHOCYTIC LEUKEMIA
不详
CANCER DISCOVERY, 2015, 5 (02) : 108 - 108
[8] TP53 Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?
Bomben, Riccardo
Zucchetto, Antonella
Gentile, Massimo
Gattei, Valter
CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4462 - 4464
[9] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Nitin Jain
Philip Thompson
Jan Burger
Alessandra Ferrajoli
Koichi Takahashi
Zeev Estrov
Gautam Borthakur
Prithviraj Bose
Tapan Kadia
Naveen Pemmaraju
Koji Sasaki
Marina Konopleva
Elias Jabbour
Naveen Garg
Xuemei Wang
Rashmi Kanagal-Shamanna
Keyur Patel
Wei Wang
Jeffrey Jorgensen
Sa Wang
Wanda Lopez
Ana Ayala
William Plunkett
Varsha Gandhi
Hagop Kantarjian
Susan O’Brien
Michael Keating
William G. Wierda
Leukemia, 2021, 35 : 3421 - 3429
[10] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Jain, Nitin
Thompson, Philip
Burger, Jan
Ferrajoli, Alessandra
Takahashi, Koichi
Estrov, Zeev
Borthakur, Gautam
Bose, Prithviraj
Kadia, Tapan
Pemmaraju, Naveen
Sasaki, Koji
Konopleva, Marina
Jabbour, Elias
Garg, Naveen
Wang, Xuemei
Kanagal-Shamanna, Rashmi
Patel, Keyur
Wang, Wei
Jorgensen, Jeffrey
Wang, Sa
Lopez, Wanda
Ayala, Ana
Plunkett, William
Gandhi, Varsha
Kantarjian, Hagop
O'Brien, Susan
Keating, Michael
Wierda, William G.
LEUKEMIA, 2021, 35 (12) : 3421 - 3429

← 1 2 3 4 5 →